Autoimmune Disease and Subsequent Urological Cancer

No AccessJournal of UrologyAdult Urology1 Jun 2013Autoimmune Disease and Subsequent Urological Cancer Xiangdong Liu, Jianguang Ji, Asta Forsti, Kristina Sundquist, Jan Sundquist, and Kari Hemminki Xiangdong LiuXiangdong Liu Center for Primary Health Care Research, Lund University, Malmö, Sweden College of Laboratory Medicine, Hebei North University, Zhangjiakou, People's Republic of China , Jianguang JiJianguang Ji Center for Primary Health Care Research, Lund University, Malmö, Sweden , Asta ForstiAsta Forsti Center for Primary Health Care Research, Lund University, Malmö, Sweden Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany , Kristina SundquistKristina Sundquist Center for Primary Health Care Research, Lund University, Malmö, Sweden , Jan SundquistJan Sundquist Center for Primary Health Care Research, Lund University, Malmö, Sweden Stanford Prevention Research Center, Stanford University School of Medicine, California , and Kari HemminkiKari Hemminki Center for Primary Health Care Research, Lund University, Malmö, Sweden Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany View All Author Informationhttps://doi.org/10.1016/j.juro.2012.12.014AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We examined the subsequent risk and prognosis of urological cancer in individuals diagnosed with autoimmune disease. Materials and Methods: We systematically analyzed the risk and prognosis of prostate, kidney and bladder cancers in individuals diagnosed with any of 33 autoimmune diseases based on a national Swedish database for 1964 through 2008. The SIR and HR were calculated for subsequent urological cancers between 1964 and 2008 in individuals hospitalized for autoimmune disease. Results: An increased SIR for urological cancer was recorded after 26 autoimmune diseases. An increased HR for cancer specific survival was noted after 4 autoimmune diseases and for overall survival after 18. The highest SIRs were seen for kidney cancer after polyarteritis nodosa (2.85) and polymyositis/dermatomyositis (2.68), and for bladder cancer after polymyositis/dermatomyositis (2.45). The highest risk of prostate cancer (1.70) was observed after polyarteritis nodosa. SIRs were lower during followup from 1990 to 2008 compared to the previous period. Individuals diagnosed with prostate and kidney cancers showed an improved cancer specific prognosis, in contrast to the poorer overall prognosis for all 3 urological cancers. Conclusions: The risk of urological cancer was increased after all autoimmune diseases. The most significant changes after individual autoimmune diseases were toward higher risk. Survival data were reassuring since autoimmune disease only marginally influences the prognosis of cancer specific mortality. However, overall survival was decreased for the 3 types of cancer. References 1 : Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol2012; 42: 71. Google Scholar 2 : The Autoimmune Diseases. New York: Academic Press2006. Google Scholar 3 : Meta-analysis of genome-wide linkage studies across autoimmune diseases. Eur J Hum Genet2009; 17: 236. Google Scholar 4 Cancer Incidence in Sweden 2010. Stockholm: National Board of Health and Welfare2010. Google Scholar 5 : Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control2008; 19: 887. Google Scholar 6 : Risk of malignancy among patients with rheumatic conditions. Int J Cancer2000; 88: 497. Google Scholar 7 : Cancer risk among patients hospitalized for type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med2010; 27: 791. Google Scholar 8 : Cancer risks in ulcerative colitis patients. Int J Cancer2008; 123: 1417. Google Scholar 9 : Cancer risks in Crohn disease patients. Ann Oncol2009; 20: 574. Google Scholar 10 : Survival of cancer in patients with rheumatoid arthritis: a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer. Rheumatology (Oxford)2011; 50: 1513. Google Scholar 11 : Survival in cancer patients hospitalized for inflammatory bowel disease in Sweden. Inflamm Bowel Dis2011; 17: 816. Google Scholar 12 : Familial risks for chronic obstructive pulmonary disease among siblings based on hospitalizations in Sweden. J Epidemiol Community Health2008; 62: 398. Google Scholar 13 : Familial risks for asthma among twins and other siblings based on hospitalizations in Sweden. Clin Exp Allergy2007; 37: 1320. Google Scholar 14 : Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classification of Tumours. Lyon: IARC2000. Google Scholar 15 : Prostate cancer screening, changing age-specific incidence trends and implications on familial risk. Int J Cancer2005; 113: 312. Google Scholar 16 : Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. J Hepatol2012; 55: 522. Google Scholar 17 : Malignancy in autoimmune diseases. J Autoimmun1992; 5: 363. Google Scholar 18 : Paradoxical roles of the immune system during cancer development. Nat Rev Cancer2006; 6: 24. Google Scholar 19 : Progress in human tumour immunology and immunotherapy. Nature2001; 411: 380. Google Scholar 20 : Occupational risk factors for kidney cancer: a cohort study in Sweden. World J Urol2005; 23: 271. Google Scholar 21 : Familial bladder cancer and the related genes. Curr Opin Urol2011; 21: 386. Google Scholar 22 : Comparability of cancer identification among Death Registry, Cancer Registry and Hospital Discharge Registry. Int J Cancer2012; 131: 2085. Google Scholar 23 : External review and validation of the Swedish national inpatient register. BMC Public Health2011; 11: 450. Google Scholar 24 : Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists. Ann Rheum Dis2005; 64: 6. Google Scholar 25 : Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum2003; 48: 963. Google Scholar 26 : Celiac disease and risk of subsequent type 1 diabetes: a general population cohort study of children and adolescents. Diabetes Care2006; 29: 6. Google Scholar 27 : Etiological and biological aspects of cigarette smoking in rheumatoid arthritis. Inflamm Allergy Drug Targets2009; 8: 364. Google Scholar 28 : Occupational exposures and lung cancer: adjustment for unmeasured confounding by smoking. Epidemiology2010; 21: 181. Google Scholar © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited by (2018) Reply by AuthorsJournal of Urology, VOL. 191, NO. 2, (309-309), Online publication date: 1-Feb-2014. Volume 189Issue 6June 2013Page: 2262-2268 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.Keywordskidneyurologic neoplasmsautoimmune diseasesprostateurinary bladderMetricsAuthor Information Xiangdong Liu Center for Primary Health Care Research, Lund University, Malmö, Sweden College of Laboratory Medicine, Hebei North University, Zhangjiakou, People's Republic of China More articles by this author Jianguang Ji Center for Primary Health Care Research, Lund University, Malmö, Sweden More articles by this author Asta Forsti Center for Primary Health Care Research, Lund University, Malmö, Sweden Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany More articles by this author Kristina Sundquist Center for Primary Health Care Research, Lund University, Malmö, Sweden More articles by this author Jan Sundquist Center for Primary Health Care Research, Lund University, Malmö, Sweden Stanford Prevention Research Center, Stanford University School of Medicine, California More articles by this author Kari Hemminki Center for Primary Health Care Research, Lund University, Malmö, Sweden Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany More articles by this author Expand All Advertisement PDF downloadLoading ...